Home Biosimilar Antibodies Angiogenesis FGFR Burosumab (Anti-FGF23)
For research use only. Not for use in humans.

Burosumab (Anti-FGF23)

Synonyms: FGF23

Burosumab (Anti-FGF23) is a neutralizing antibody, targeting human fibroblast growth factor 23 (FGF23). It can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia. MW: 145.5 KD.

Burosumab (Anti-FGF23)

Quality Control

Batch: A249901 Purity: 99% Protein concentration: 5.19mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation FGFR FGFR1 FGFR2 FGFR3 FGFR4 Others
PD173074 125 VEGFR2
Dovitinib (TKI-258) 53 FLT3,c-Kit,VEGFR3/FLT4
AZD4547 (Fexagratinib) 147 KDR
Danusertib (PHA-739358) 46 Aurora A,Abl,TrkA
Brivanib (BMS-540215) 15 VEGFR2,Flk1,VEGFR1
ENMD-2076 13 FLT3,RET,Aurora A
MK-2461 5 c-Met (M1250T),c-Met (Y1235D),c-Met (Y1230H)
Brivanib Alaninate (BMS-582664) 2 VEGFR2,Flk1,VEGFR1
Tyrphostin AG 1296 14 PDGFR,c-Kit (Swiss 3T3)
SSR128129E 10
Irpagratinib 0
R1530 0 VEGFR2
FIIN-3 0
Lucitanib (E3810) hydrochloride 1 VEGFR1,VEGFR3,VEGFR2
Rogaratinib 0
Sulfatinib 2 VEGFR3,VEGFR1,CSF1R
ODM-203 0 VEGFR3,VEGFR2,VEGFR1
Futibatinib (TAS-120) 17
ASP5878 3
Derazantinib 4 RET,DDR2,PDGFRβ
H3B-6527 15
Roblitinib (FGF401) 6
PRN1371 2 CSF1R
PD-166866 15
Fisogatinib (BLU-554) 12
S49076 1 Met,Mer,Axl
NSC12 3 FGF3,FGF8b,FGF22
ON123300 4 CDK4/CyclinD1,ARK5,RET
SU 5402 25 VEGFR2,PDGFRβ
BLU9931 21
FIIN-2 5
Dovitinib (TKI258) Lactate monohydrate 31 FLT3,c-Kit,VEGFR3/FLT4
Zoligratinib (Debio-1347) 12
LY2874455 15 VEGFR2
Ferulic Acid 6
Resigratinib 0
Lirafugratinib (RLY-4008) 0
Masitinib mesylate 2 FAK,human recombinant c-Kit,LynB
BO-264 0 TACC3
SKLB 610 2 PDGFR,VEGFR2
Alofanib (RPT835) 6
Gambogenic acid 5 EZH2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Burosumab (Anti-FGF23) is a neutralizing antibody, targeting human fibroblast growth factor 23 (FGF23). It can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia. MW: 145.5 KD.

Product Details

CAS No. 1610833-03-8
Molecular Weight 144 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05509595 COMPLETED Drug: Burosumab Fibrous Dysplasia Of Bone National Institute of Dental and Craniofacial Research (NIDCR) 2022-12-07 PHASE2
NCT04842032 COMPLETED Drug: KRN23 X-linked Hypophosphatemia (XLH) Kyowa Kirin Co., Ltd. 2021-11-01 PHASE4
NCT05357573 COMPLETED Drug: KRN23 Tumor-Induced Osteomalacia (TIO) Kyowa Kirin Co., Ltd. 2022-09-07 PHASE4
NCT04188964 COMPLETED Drug: Burosumab X-linked Hypophosphatemia (XLH) Kyowa Kirin Pharmaceutical Development Ltd 2020-02-26 PHASE1; PHASE2
NCT04842019 COMPLETED Drug: KRN23 X-linked Hypophosphatemia (XLH) Kyowa Kirin Co., Ltd. 2021-09-28 PHASE4
NCT04695860 COMPLETED Drug: Burosumab X-linked Hypophosphatemia Wuerzburg University Hospital 2021-01-07 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-02-02)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.